Laboratory Corporation of America Stock (NYSE:LH)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$227.34

52W Range

$191.97 - $238.47

50D Avg

$217.82

200D Avg

$214.36

Market Cap

$18.80B

Avg Vol (3M)

$569.01K

Beta

1.04

Div Yield

$2.88 (1.61%)

LH Company Profile


Laboratory Corporation of America Holdings operates as a global life sciences company that provides vital information to help doctors, hospitals, pharmaceutical companies, researchers, and patients make clear and confident decisions. It operates in two segments, Labcorp Diagnostics (Dx) and Labcorp Drug Development (DD). It offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid tests, PAP tests, hemoglobin A1C and vitamin D, prostate-specific antigens, tests for sexually transmitted diseases, hepatitis C tests, microbiology cultures and procedures, and alcohol and other substance-abuse tests. The company also provides specialty testing services comprising gene-based and esoteric testing; advanced tests target specific diseases, including anatomic pathology/oncology, cardiovascular disease, coagulation, diagnostic genetics, endocrinology, infectious disease, women's health, pharmacogenetics, and parentage and donor testing; and occupational testing services, medical drug monitoring services, chronic disease programs, and kidney stone prevention tests. It provides online and mobile applications to enable patients to check test results; and online applications for managed care organizations and accountable care organizations. It offers end-to-end drug development, medical device, and companion diagnostic development solutions from early-stage research to clinical development and commercial market access. It serves managed care organizations, pharmaceutical, biotechnology, medical device and diagnostics companies, governmental agencies, physicians and other healthcare providers, hospitals and health systems, employers, patients and consumers, contract research organizations, and independent clinical laboratories. Laboratory Corporation of America Holdings has a collaboration agreement with Tigerlily Foundation to increase clinical trial diversity for women of color. The company was incorporated in 1994 and is headquartered in Burlington, North Carolina.

Show More

Industry

Medical - Diagnostics & Research

Sector

Healthcare

Exchange

NYSE

ADR

-

Country

US

Employees

67,000

IPO Date

Mar 29, 1990

Website

LH Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 22Dec 21Dec 19
Drug Development$5.71B$11.69B-
Diagnostics$9.20B$20.73B-
Covance Drug Development--$4.58B
LabCorp Diagnostics--$7.00B

Fiscal year ends in Dec 23 | Currency in USD

LH Financial Summary


Dec 23Dec 22Dec 21
Revenue$12.16B$14.88B$16.12B
Operating Income$1.12B$1.77B$3.26B
Net Income$418.00M$1.28B$2.38B
EBITDA$1.70B$2.74B$4.12B
Basic EPS$4.77$14.05$24.60
Diluted EPS$4.77$13.97$24.39

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 01, 24 | 3:15 PM
Q1 24Apr 25, 24 | 12:00 AM
Q4 23Feb 15, 24 | 1:08 PM

Peer Comparison


TickerCompany
HUMHumana Inc.
HOLXHologic, Inc.
UHSUniversal Health Services, Inc.
DGXQuest Diagnostics Incorporated
WATWaters Corporation